Join Dr David Cook, CSO at Blueberry Therapeutics as he discusses “Understanding what makes a good drug discovery project: can we ever really predict success?

David has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London and three years of post-doctoral experience. David has worked in the pharmaceutical industry for AstraZeneca for more than 17 years in a wide variety of R&D roles both in the UK and the US. He initially worked in the respiratory and inflammation area and was responsible for identifying the mode-of-action for a new class of immunosuppressive. David moved into the safety functions six years ago since when he has led a number of global initiatives developing new approaches to improve the understanding of safety in new medicines. David has experience across the drug discovery and development pipeline from target selection to supporting market products and has worked on projects in many disease areas including Respiratory and Inflammation, Infection, Cardiovascular, CNS and Pain and Oncology.